Viking Therapeutics (VKTX) Other Non-Current Assets (2014 - 2026)
Viking Therapeutics (VKTX) reported Other Non-Current Assets of $33000.0 for Q1 2026, down 28.26% on a YoY basis from $46000.0 in Q1 2025, and down 28.26% sequentially from $46000.0 in Q4 2025.
Viking Therapeutics (VKTX) Other Non-Current Assets (2014 - 2026) Analysis & Trends
Viking Therapeutics (VKTX) has 13 years of Other Non-Current Assets data on file, last reported at $33000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets fell 28.26% year-over-year to $33000.0; the trailing twelve-month figure through Mar 2026 stood at $33000.0 (down 28.26% YoY), and the FY2025 full-year result was $46000.0, changed 0.0% from the prior year.
- Other Non-Current Assets slipped to $33000.0 in Q1 2026, from $46000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $46000.0 in Q3 2024 to a low of $33000.0 in Q1 2022.
- A 5-year average of $37588.2 and a median of $33000.0 in 2022 frame the typical range for Other Non-Current Assets.
- Across the five-year window, Other Non-Current Assets jumped 39.39% in 2024 and dropped 28.26% in 2026, its largest moves.
- Tracing VKTX's Other Non-Current Assets over 5 years: stood at $33000.0 in 2022, then changed by 0.0% to $33000.0 in 2023, then soared by 39.39% to $46000.0 in 2024, then changed by 0.0% to $46000.0 in 2025, then declined by 28.26% to $33000.0 in 2026.
- Business Quant data shows VKTX's Other Non-Current Assets at $33000.0 in Q1 2026, $46000.0 in Q4 2025, and $46000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Viking Therapeutics | 4.09 Bn | 4.09 Bn | - | 33,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33,000.00 |
| Dec 31, 2025 | 46,000.00 |
| Sep 30, 2025 | 46,000.00 |
| Jun 30, 2025 | 46,000.00 |
| Mar 31, 2025 | 46,000.00 |
| Dec 31, 2024 | 46,000.00 |
| Sep 30, 2024 | 46,000.00 |
| Jun 30, 2024 | 33,000.00 |
| Mar 31, 2024 | 33,000.00 |
| Dec 31, 2023 | 33,000.00 |
| Sep 30, 2023 | 33,000.00 |
| Jun 30, 2023 | 33,000.00 |
| Mar 31, 2023 | 33,000.00 |
| Dec 31, 2022 | 33,000.00 |
| Sep 30, 2022 | 33,000.00 |
| Jun 30, 2022 | 33,000.00 |
| Mar 31, 2022 | 33,000.00 |
| Dec 31, 2021 | 33,000.00 |
| Dec 31, 2020 | 29,000.00 |
| Sep 30, 2020 | 29,000.00 |